Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | OGG1 | O15527 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30435963 | 1.00 | BTN3A1 (0.41) | BTN3A1KDM4EALDH1A1PGRGAA | |
| SCHEMBL28401524 | 1.00 | BTN3A1 (0.41) | BTN3A1KDM4EALDH1A1PGRGAA | |
| SCHEMBL29692333 | 1.00 | BTN3A1 (0.41) | BTN3A1KDM4EALDH1A1PGRGAA | |
| SCHEMBL23044633 | 0.91 | MEN1 (0.39) | BTN3A1KDM4EALDH1A1PGRGAA | |
| SCHEMBL28986476 | 0.88 | BTN3A1 (0.41) | BTN3A1KDM4EALDH1A1OGG1HTT | |
| SCHEMBL29895522 | 0.88 | BTN3A1 (0.41) | BTN3A1KDM4EALDH1A1OGG1HTT | |
| SCHEMBL20840403 | 0.88 | ALDH1A1 (0.39) | BTN3A1KDM4EALDH1A1PGRGAA | |
| SCHEMBL21192831 | 0.88 | ALDH1A1 (0.39) | BTN3A1KDM4EALDH1A1PGRGAA | |
| SCHEMBL23827926 | 0.88 | ALDH1A1 (0.39) | BTN3A1KDM4EALDH1A1PGRGAA | |
| SCHEMBL28529772 | 0.88 | ALDH1A1 (0.39) | BTN3A1KDM4EALDH1A1PGRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11351186-B2 | 4′-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication | RIBOSCIENCE LLC (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210046100-A1 | 4'-FLUORO-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | RIBOSCIENCE LLC | 2021-02-18 | — | — | US | disclosed |
| US-10682369-B2 | 4′-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication | RIBOSCIENCE LLC (US) | 2020-06-16 | — | — | US | disclosed |
| US-20190231804-A1 | 4'-FLUORO-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | RIBOSCIENCE LLC | 2019-08-01 | — | — | US | disclosed |
| WO-2019060740-A1 | 4'-FLUORO-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | RIBOSCIENCE LLC (US) | 2019-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190231804-A1 | 4'-FLUORO-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | NSUN2, RNGTT, RNMT | BTN3A1 4527/4885KDM4E 1212/4885ALDH1A1 1949/4885 |
| US-10682369-B2 | 4′-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication | NSUN2, RNGTT, RNMT | BTN3A1 4553/4885KDM4E 1204/4885ALDH1A1 1954/4885 |
| US-11351186-B2 | 4′-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication | NSUN2, RNGTT, RNMT | BTN3A1 4553/4885KDM4E 1204/4885ALDH1A1 1954/4885 |
| US-20210046100-A1 | 4'-FLUORO-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | NSUN2, RNGTT, RNMT | BTN3A1 4527/4885KDM4E 1212/4885ALDH1A1 1949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.